MARKET

OXFD

OXFD

Oxford Immunotec
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.64
-0.23
-1.79%
After Hours: 12.64 0 0.00% 16:00 09/21 EDT
OPEN
12.68
PREV CLOSE
12.87
HIGH
12.92
LOW
12.40
VOLUME
50.97K
TURNOVER
--
52 WEEK HIGH
17.77
52 WEEK LOW
8.37
MARKET CAP
328.08M
P/E (TTM)
-21.3694
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oxford Immunotec (OXFD) Reports Q2 Loss, Lags Revenue Estimates
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -428.57% and -4.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 13:55
Oxford Immunotec Sees Q3 Sales $18M-$19M vs $15M Estimate
Benzinga · 08/04 11:40
Oxford Immunotec Global Q2 EPS $(0.37) Misses $(0.30) Estimate, Sales $5.83M Beat $5.80M Estimate
Oxford Immunotec Global (NASDAQ:OXFD) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 1950 percent decrease over earnings of $0.02 per
Benzinga · 08/04 11:40
Oxford Immunotec Reports Second Quarter 2020 Financial Results
* Second quarter revenue of $5.8 million, a decrease of 70% compared to prior year period, due to the impact of COVID-19 * Ended the quarter with approximately $165 million of cash and cash equivalents * Third quarter revenue estimated to be between $18 -
GlobeNewswire · 08/04 11:00
Earnings Preview: Oxford Immunotec (OXFD) Q2 Earnings Expected to Decline
Oxford Immunotec (OXFD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/28 16:33
Did Hedge Funds Make The Right Call On Oxford Immunotec Global PLC (OXFD) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 07/28 14:48
Oxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 21, 2020 -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today.
GlobeNewswire · 07/21 13:15
Oxford Immunotec Announces Agreement With Stop TB Partnership
Benzinga · 07/20 13:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OXFD stock price target is 18.33 with a high estimate of 21.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 28.92M
% Owned: 111.44%
Shares Outstanding: 25.96M
TypeInstitutionsShares
Increased
26
3.29M
New
24
-1.43M
Decreased
19
2.70M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.41%
Healthcare Equipment & Supplies
-1.43%
Key Executives
Chairman/Independent Director
Patrick Balthrop
Chief Executive Officer/Director
Peter Wrighton-Smith
Chief Financial Officer
Matthew McLaughlin
General Counsel/Secretary
Janet Kidd
Independent Director
Ronald Andrews
Independent Director
Mark Klausner
Independent Director
Patricia Randall
Independent Director
Herman Rosenman
Independent Director
Richard Sandberg
Independent Director
James Tobin
Independent Director
Andrew Walton
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average OXFD stock price target is 18.33 with a high estimate of 21.00 and a low estimate of 16.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OXFD
Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oxford Immunotec Global PLC stock information, including NASDAQ:OXFD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OXFD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OXFD stock methods without spending real money on the virtual paper trading platform.